[ad_1] Johnson & Johnson (JNJ) reported strong second – quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. J & J’s second-quarter reported sales rose 6.3% year-over-year to $25.53 billion, exceeding the Refinitv consensus estimate of $24.63 billion. (On an…
[ad_1] Kenvue shares fell on Thursday even though the consumer health company beat second-quarter revenue and earnings expectations in the its first quarterly report since it spun out from Johnson & Johnson two months ago. The company, formerly J&J’s consumer health division, also issued an upbeat sales outlook for 2023. But Kenvue CEO Thibaut Mongon noted during an earnings call…
[ad_1] Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations, and lifted its full-year guidance as sales from the company’s medtech business jumped. The medtech division provides devices for surgeries, orthopedics and vision. The company is benefitting from a rebound in demand for non-urgent surgeries among older adults,…
[ad_1] Pavlo Gonchar | LightRocket | Getty Images Johnson & Johnson on Tuesday sued the Biden administration over Medicare’s new powers to slash drug prices, making it the third pharmaceutical company to challenge the controversial provision of the Inflation Reduction Act. The lawsuit filed in federal district court in New Jersey argues the Medicare negotiations…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Earnings and inflation Watch J & J Strong outlook for Meta 1. Earnings and inflation U.S. stocks edged higher Monday, with the Dow jumping over 150 points, rallying after…
[ad_1] Investors hoping to capture more upside from artificial intelligence could turn to a sector that’s underperformed this year, and maybe not immediately associated with AI: Health care. A handful of large tech names surged in the first half thanks to a mania for all things tied to artificial intelligence. Apple, for example, last week…
[ad_1] Traders work on the floor of the New York Stock Exchange during morning trading, April 10, 2023. Michael M. Santiago | Getty Images The pharmaceutical industry’s largest lobbying group and two other organizations Wednesday sued the Biden administration over Medicare’s new powers to slash drug prices for seniors under the Inflation Reduction Act. Pharmaceutical…
[ad_1] A pharmacist prepares to administer Covid-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center in Chicago, Illinois, Sept. 9, 2022. Scott Olson | Getty Images The U.S. Food and Drug Administration‘s Covid strain selection for the next round of shots puts Pfizer, Moderna…
[ad_1] If you were to tell me that Club names Estee Lauder (EL) or Danaher (DHR) would ever miss their quarters not once but twice, I would have told you to go get your head examined. These are clockwork beat and raise companies, which is why it’s so hard to value them now. Johnson &…
[ad_1] Chief Executive Officers of pharmaceutical companies testify before the Senate Finance Committee on “Drug Pricing in America: A Prescription for Change, Part II” February 26, 2019 in Washington, DC. From left to right are Richard A. Gonzalez, chairman and CEO of AbbVie Inc; Pascal Soriot, executive director and CEO of AstraZeneca; Giovanni Caforio, chairman…
